Pharmacia & Upjohn S.p.a.

Farmitalia Carlo Erba S.r.l.

Pharmacia S.p.a.

Nerviano Medical Sciences S.r.l.

Pharmacia Corporation

Dario Ballinari

Franco Buzzetti

Antonio Longo

Maria Gabriella Brasca

Antonino Suarato

Michele Caruso

Jacqueline Lansen

Angelo Crugnola

Tiziano Bandiera

Carlo Battistini

Sergio Vioglio

Antonella Ermoli

Enrico Pesenti

Fabrizio Orzi

Mariangela Mariani

Antonella Ciavolella

Sergio Penco

Italo Beria

Maria Menichincheri

Alberto Bargiotti

Mauro Angiolini

Barbara Valsasina

Jurgen Moll

Alessia Montagnoli

Domenico Fusar Bassini

Juergen Moll

Valter Domenico Croci

Maurizio D'Incalci

Luisella Bonomini

Markus Gude

Jean-Yves Trosset

Felicita Greco

Gabriella Maria Brasca

The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.

Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent

The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors. 

Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent

The invention provides pyrido[2,3-d]pyrimidin-7(8H)-one telomerase inhibitors of the formulawhere R1, R2 are as defined herein. The invention also provides methods for preparing the compounds of formula I, methods of using the compounds to treat diseases such as cancer, and pharmaceutical compositions comprising the compounds.

Pyridopyrimidinones derivatives as telomerase inhibitors

Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase

The present invention provides the new use in the treatment of amyloidosis with the anthracyclinone of formula (A) wherein R1, R2, R3, R4, and R5, are appropriate substituents. Some compounds of formula (A) are novel. Processes for their preparation and pharmaceutical composition containing them are also described.

Anthracyclinone derivatives and their use in amyloidosis

Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase

Anthracyclinone derivatives

Aryl and heteroaryl purine compounds

Substituted quinolymethylen-oxindole analogues as tyrosine kinase

Substituted indolylmethylene-oxindole analogues as tyrosine kinase

Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase

Anthracycline derivatives

Use of anthracyclinone derivatives in amyloidosis

Substituted 3-arylidene-7-azaoxindole compounds and process for their

Substituted azaindolylidene compounds and process for their preparation

Growing community of inventors

San Donato Milanese, Italy

Dario Ballinari